GTx Inc. (NASDAQ:GTXI) is a Memphis-based biopharmaceutical company founded in 1997 with a pipeline of synthetic small, hormone-mimic type drugs, the "selective androgen receptor modulators" (SARMs) and "selective estrogen receptor modulators" (SERMs). Today, a SERM, Capesaris (GTX-758), currently in a Phase IIb clinical trial (G200712), is discussed. It has been in 8 previous clinical trials. Capesaris is a SERM α-agonist under development for first- or second-line treatment of advanced or metastatic prostate cancers, i.e., Stages III and IV, here abbreviated as "m-PCA." The treatment goal for m-PCA is total systemic (body wide) androgen suppression or blockade, referred to as (surgical or chemical) castration. GTx's lead drug, enobosarm, was discussed in 2 previous articles. The second...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|